Phospho-PAK1 (Ser199) Antibody

Shipped with Ice Packs
In Stock

Product Specs

Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship the products within 1-3 business days of receiving your order. Delivery times may vary depending on the shipping method and destination. For specific delivery times, please consult your local distributors.
Synonyms
ADRB2 antibody; Alpha PAK antibody; Alpha-PAK antibody; MGC130000 antibody; MGC130001 antibody; p21 activated kinase 1 antibody; p21 protein (Cdc42/Rac) activated kinase 1 antibody; p21-activated kinase 1 antibody; p21/Cdc42/Rac1 activated kinase 1 (yeast Ste20 related) antibody; p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) antibody; p65 PAK antibody; p65-PAK antibody; P68-PAK antibody; PAK alpha antibody; PAK-1 antibody; Pak1 antibody; PAK1_HUMAN antibody; Paka antibody; PAKalpha antibody; Protein kinase MUK2 antibody; Rac/p21-activated kinase antibody; Serine/threonine-protein kinase PAK 1 antibody; STE20 homolog yeast antibody
Target Names
Uniprot No.

Target Background

Function
p21-activated kinase 1 (PAK1) is a serine/threonine protein kinase involved in various intracellular signaling pathways downstream of integrins and receptor-type kinases. It plays a crucial role in regulating cytoskeleton dynamics, cell adhesion, migration, proliferation, apoptosis, mitosis, and vesicle-mediated transport processes. PAK1 directly phosphorylates BAD, protecting cells from apoptosis. Activation occurs through interactions with CDC42 and RAC1, acting as a GTPase effector that links the Rho-related GTPases CDC42 and RAC1 to the JNK MAP kinase pathway. PAK1 phosphorylates and activates MAP2K1, mediating the activation of downstream MAP kinases. It is involved in reorganizing the actin cytoskeleton, actin stress fibers, and focal adhesion complexes. PAK1 phosphorylates the tubulin chaperone TBCB, contributing to the regulation of microtubule biogenesis and organization of the tubulin cytoskeleton. It also plays a role in regulating insulin secretion in response to elevated glucose levels. PAK1 forms a ternary complex with DVL1 and MUSK, which is essential for MUSK-dependent regulation of AChR clustering during the formation of the neuromuscular junction (NMJ). PAK1 activity is inhibited in apoptotic cells, potentially due to the binding of CDC2L1 and CDC2L2. PAK1 phosphorylates MYL9/MLC2, RAF1 (at 'Ser-338' and 'Ser-339'), SNAI1 (at 'Ser-246'), and NR3C2 in podocytes, promoting their respective functions. PAK1 is essential for ACKR2-induced phosphorylation of LIMK1 and cofilin (CFL1), facilitating the upregulation of ACKR2 from the endosomal compartment to the cell membrane, enhancing its efficiency in chemokine uptake and degradation. In synapses, PAK1 regulates F-actin cluster formation mediated by SHANK3, potentially through CFL1 phosphorylation and inactivation. PAK1 plays a role in RUFY3-mediated facilitation of gastric cancer cell migration and invasion. In response to DNA damage, PAK1 phosphorylates MORC2, activating its ATPase activity and promoting chromatin remodeling. In neurons, PAK1 plays a crucial role in regulating GABA(A) receptor synaptic stability and GABAergic inhibitory synaptic transmission through its role in F-actin stabilization. In hippocampal neurons, PAK1 is essential for the formation of dendritic spines and excitatory synapses, a function dependent on kinase activity and potentially exerted by regulating actomyosin contractility through the phosphorylation of myosin II regulatory light chain (MLC). Along with GIT1, PAK1 positively regulates microtubule nucleation during interphase.
Gene References Into Functions
  1. PAK1 gene silencing decreases proliferation of MHCC97-H cells, HepG2 cells, and cells in xenograft tumors through the p53/p21 pathway. PMID: 29802374
  2. PAK1 silencing attenuated cell cycle progression, inducing apoptosis. Inhibition of PAK1 expression reduced tumor sizes and masses by modulating CREB expression and activation. PMID: 30282071
  3. Once activated, c-Abl kinase regulated the activity of Vav1, which further affected Rac1/PAK1/LIMK1/cofilin signaling pathway. PMID: 29058761
  4. The nuclear functions of PAK1 and its role in the regulation of DNA damage repair are reviewed. PMID: 29597073
  5. PAK1 is upregulated in cutaneous T cell lymphoma. PAK1 silencing induced apoptosis and inhibited cell growth by stimulating the expression of PUMA and p21. PMID: 29307600
  6. Results show that JMJD6 regulates the alternative splicing of PAK1 in melanoma cells. PMID: 29187213
  7. PAK1 expression, evaluated by immunohistochemistry, was positively correlated with pERK and beta-catenin expression in lung tumors. Patients with high-PAK1, high-pERK, and high-nuclear beta-catenin tumors more frequently showed an unfavorable response to cisplatin-based chemotherapy when compared to their counterparts. PMID: 27713506
  8. PKC-zeta may be responsible for the abnormal growth, proliferation, and migration of metastatic LOVO colon cancer cells via PKC-zeta/Rac1/Pak1/beta-Catenin pathway. PMID: 29408512
  9. High expression of PAK1 is associated with invasion of gastric cancer. PMID: 28534988
  10. Molecular modelling studies of PAK1 with its major interacting partners RHOA and STAT3 revealed potential network gene elements in breast invasive carcinoma. PMID: 27456030
  11. miR4855p reverses EMT and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. This study suggests that PAK1 plays an essential role in the progression of OSCC and it is a potential therapeutic target for OSCC. PMID: 28535002
  12. Because reduced PAK1 activity impaired FA/BRCA function, inhibition of this kinase in PAK1 amplified and/or overexpressing breast cancer cells represents a plausible strategy for expanding the utility of PARP inhibitors to FA/BRCA-proficient cancers. PMID: 27740936
  13. Overall, the authors find that p27 directly promotes cell invasion by facilitating invadopodia turnover via the Rac1/PAK1/Cortactin pathway. PMID: 28287395
  14. Results show that Pak1 is overexpressed in breast cancer cells and tissues, and found that Pak1 is a hormone responsive gene, whose expression can be modulated by steroid hormones, estrogen (E2) and progesterone (P4). Pak1 promoter analysis showed that PR mediates promoter activity via its binding to PRE present on the Pak1 promoter. PMID: 29274909
  15. PAK1 confers TKI resistance in EGFR-mutant cells as well as in EGFR-wild-type cells. PMID: 27178741
  16. Our findings offer an insight for the new drug development of PAK1 inhibitor. We also provide a possible explanation for the phenomenon that the application of the chlorhexidine in peritoneal lavage inhibited the development of tumor. PMID: 29146188
  17. To our knowledge, this is the first study illustrating the mechanistic role of Pak1 in causing gemcitabine resistance via multiple signaling crosstalks, and hence Pak1-specific inhibitors will prove to be a better adjuvant with existing chemotherapy modality for pancreatic ductal adenocarcinoma (PDAC) PMID: 27117533
  18. Studies indicate that PAK1 expression may be a predictive marker of overall survival and disease-specific survival in patients with solid tumors. PMID: 27027431
  19. Results from our analysis showed that Pak1 overexpression, knockdown and Pak1 knockout cell line models showed that Pak1 confers protection to keratinocytes from UV-B-induced apoptosis and DNA damage via ATR. PMID: 28692051
  20. the oxidative stress-induced down-regulation of PAK1 activity could be involved in the loss of mesencephalic dopaminergic neurons. PMID: 27121078
  21. the expression of PAK1 is inversely correlated with the level of miR-494 in human breast cancer samples. Furthermore, re-expression of PAK1 partially reverses miR-494-mediated proliferative and clonogenic inhibition as well as migration and invasion suppression in breast cancer cells PMID: 28055013
  22. Our study revealed that PAK1 may play a crucial role in the progression of OSCC. Studying the role of PAK1 and its substrates is likely to enhance our understanding of oral carcinogenesis and potential therapeutic value of PAKs in oral cancer. PMID: 27229476
  23. The effect of PAK1 modulation on tumorigenesis, and on resistance to treatment with 5-fluorouracil (5-FU), was measured by sphere formation in vitro and by growth of xenografted tumors in vivo. The results show that PAK1 activity correlated with the expression of CSC markers and the CD44 isoform profile, and with tumor growth both in vitro and in vivo. PMID: 27260988
  24. this study shows that PAK1 may be a potential tumor marker and therapeutic target of prostate cancer PMID: 28186966
  25. Our results from clinical samples also suggest that Threonine 209 phosphorylation by Pak1 could be a potential therapeutic target and of great clinical relevance with implications for Runx3 inactivation in cancer cells where Runx3 is known to be oncogenic. The findings presented in this study provide evidence of Runx3-Threonine 209 phosphorylation as a molecular switch in dictating the tissue-specific dualistic functions PMID: 26898755
  26. Abnormalities in the PAK1 and PAK3 mRNA levels as well as their altered coexpression patterns were observed in the postmortem brain of subjects with depression. Dysregulated PAK1/PAK3 dependent signaling may be a key factor responsible for volumetric abnormalities observed in the hippocampus and in the prefrontal cortex in depression resulting in altered connectivity of these regions. PMID: 27474226
  27. Short-term treatment of nascent melanoma tumors with PAK inhibitors that block RhoJ signaling halts the growth of BRAF mutant melanoma tumors in vivo and induces apoptosis in melanoma cells in vitro via a BAD-dependent mechanism PMID: 28753606
  28. these data strongly support a critical interplay between prolactin and estrogen via PAK1 and suggest that ligand-independent activation of ERalpha through prolactin/PAK1 may impart resistance to anti-estrogen therapies. PMID: 26944939
  29. Given the central role of p21-Activated kinase 1 (PAK1) in vital signaling pathways, studies suggest that clinical development of PAK1 inhibitors will require careful investigation of their safety and efficacy. PMID: 28202661
  30. These findings suggest that small-molecule inhibitors of Pak1 may have a therapeutic role in the ~25% of ovarian cancers characterized by PAK1 gene amplification. PMID: 26257058
  31. autocrine VEGF and IL-8 promoted endothelial cell migration via the Src/Vav2/Rac1/PAK1 signaling pathway. PMID: 28278510
  32. These data provide insight into the mechanisms guiding PRL-mediated breast cancer cell motility and invasion and highlight a significant role for phosphoTyr-PAK1 in breast cancer metastasis. PMID: 27542844
  33. p120 participates in the progress of gastric cancer through regulating Rac1 and Pak1. PMID: 26324182
  34. The role of PAK1 in cancer drug resistance in BRAF-mutated cancer PMID: 28052407
  35. High p21-activated kinase 1 and cell division control protein 42 homolog expressions are closely related to the clinicopathological features and poor prognosis of cervical carcinoma, serving as unfavorable prognostic factors. PMID: 27060895
  36. miR7 negatively regulates PAK1 protein expression but has no effect on PAK1 mRNA expression. Knockdown of PAK1 expression markedly suppressed thyroid cancer cell proliferation, migration, and invasion. PMID: 27430434
  37. Myricetin effectively suppressed the protein expression of p21-activated kinase 1 (PAK1). PMID: 27122002
  38. overexpression of PAK1, NEK6, AURKA, and AURKB genes in patients with Colorectal adenomatous polyp and colorectal cancer in the Turkish population. PMID: 26423403
  39. Pak1 expression is not associated with breast cancer recurrence and resistance to tamoxifen. PMID: 27056567
  40. 1alpha,25-Dihydroxy-Vitamin D3 leads to disruption of RAC1 and PAK1 activity with subsequent actin depolymerization of endometrial carcinoma cells. PMID: 27997893
  41. Study acts as a further supplement of the genetic features of neuroendocrine tumors. Somatic mutations of three potential tumor-related genes (HRAS, PAK1 and MEN1) might contribute to the tumorigenesis of thymic neuroendocrine tumors with EAS. PMID: 27913610
  42. PAK1-cofilin phosphorylation mechanism to mediate lung adenocarcinoma cells migration promoted by apelin-13 PMID: 26918678
  43. PAK-1 overexpression may be involved in colorectal carcinoma progression and could be considered an independent predictor of disease recurrence. PMID: 26884861
  44. Combination of a PAK1 inhibitor such as FRAX597 with cytotoxic chemotherapy deserves further study as a novel therapeutic approach to pancreatic cancer treatment. PMID: 26774265
  45. beta-elemene enhances radiosensitivity of gastric cancer cells by inhibiting Pak1 signaling. PMID: 26379399
  46. PAK1 nuclear translocation is ligand-dependent: only PRL but not E2 stimulated PAK1 nuclear translocation PMID: 27003261
  47. These findings indicate that genetic variants in PAK1 gene may contribute to susceptibility to lung cancer in the Chinese population. PMID: 26377044
  48. Formation of filopodia by membrane glycoprotein M6a (Gpm6a) requires actin regulator coronin-1a (Coro1a), known to regulate plasma membrane localization and activation of Rac1 and its downstream effector Pak1. PMID: 26809475
  49. This study showed that PAK1 messenger RNA levels were significantly downregulated specifically in deep layer 3 pyramidal cells in patient with schizophrenia. PMID: 25981171
  50. Data show association of G protein-coupled receptor kinase-interacting protein 1 (GIT1), p21-activated kinase interacting exchange factor (betaPIX), and p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) with centrosomes. PMID: 27012601

Show More

Hide All

Database Links

HGNC: 8590

OMIM: 602590

KEGG: hsa:5058

STRING: 9606.ENSP00000278568

UniGene: Hs.435714

Protein Families
Protein kinase superfamily, STE Ser/Thr protein kinase family, STE20 subfamily
Subcellular Location
Cytoplasm. Cell junction, focal adhesion. Cell projection, lamellipodium. Cell membrane. Cell projection, ruffle membrane. Cell projection, invadopodium. Nucleus, nucleoplasm. Chromosome. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
Tissue Specificity
Overexpressed in gastric cancer cells and tissues (at protein level).

Q&A

What are the key specifications of Phospho-PAK1 (Ser199/204) antibodies?

Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) antibodies are typically derived from rabbit sources and detect endogenous levels of these phosphorylated proteins . These antibodies show reactivity across multiple species including human, mouse, rat, and guinea pig samples . The molecular weight detected is approximately 68-74 kDa for PAK1/3 and 61-67 kDa for PAK2 . For Western blotting applications, these antibodies are commonly used at a 1:1000 dilution . Proper storage conditions generally require maintaining the antibody at -20°C, where it remains stable for approximately one year from the receipt date .

How do I distinguish between phosphorylated forms of PAK1 and PAK2 in my samples?

Distinguishing between phosphorylated forms of PAK1 and PAK2 requires careful analysis of band patterns on Western blots. PAK2 typically appears as a single dominant band at approximately 60 kDa, while PAK1 presents multiple bands between 60-70 kDa . For precise identification, you should run appropriate controls including recombinant proteins of known identity or samples with siRNA-mediated silencing of either PAK1 or PAK2 . Additionally, phospho-specific antibodies often detect bands at slightly higher positions compared to total protein antibodies, which can aid in identification . Using antibodies that specifically recognize phosphorylation at Ser199/204 for PAK1 or Ser192/197 for PAK2 will help discriminate between these related proteins.

What are the optimal conditions for detecting phospho-PAK1 (Ser199) in Western blotting?

For optimal detection of phospho-PAK1 (Ser199) by Western blotting, samples should be prepared with phosphatase inhibitors to preserve the phosphorylation state. The recommended protocol includes:

  • Use fresh cell/tissue lysates prepared in buffer containing both phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) and protease inhibitors.

  • Separate proteins on 5-20% SDS-PAGE gels for optimal resolution of PAK1 (68-74 kDa) .

  • Use a 1:1000 dilution of the primary antibody .

  • Include positive controls (cells treated with growth factors that activate PAK1) and negative controls (phosphatase-treated samples).

  • For improved specificity, consider overnight incubation with primary antibody at 4°C.

When interpreting results, be aware that PAK1 often appears as multiple bands between 60-70 kDa, with phospho-specific antibodies typically detecting bands at slightly higher positions compared to total protein antibodies .

How can I validate the specificity of phospho-PAK1 (Ser199) antibody signals?

Validating the specificity of phospho-PAK1 (Ser199) antibody signals requires multiple approaches:

  • siRNA-mediated silencing: Perform knockdown experiments targeting PAK1 to confirm signal reduction .

  • Phosphatase treatment: Treat cell lysates with alkaline phosphatase and verify signal reduction with phospho-specific antibodies .

  • Competing peptides: Pre-incubate the antibody with the phosphopeptide used as immunogen to block specific binding.

  • Phosphomimetic and phospho-null mutants: Test the antibody against PAK1 mutants where Ser199 is replaced with either alanine (phospho-null) or glutamic acid (phosphomimetic).

  • Multiple antibody comparison: Use different antibodies targeting the same phosphorylation site and compare band patterns .

Research has shown that antibody specificity can vary significantly, with some antibodies detecting non-specific bands or showing cross-reactivity with related proteins . Always include appropriate controls and be critical when interpreting results.

Why do I observe multiple bands when using phospho-PAK1 (Ser199) antibodies?

The observation of multiple bands when using phospho-PAK1 antibodies is a common occurrence that can be attributed to several factors:

  • Isoform diversity: PAK1 exists in multiple isoforms, including full-length PAK1 and variants like PAK1Δ15 .

  • Post-translational modifications: Different phosphorylation states can alter the protein's electrophoretic mobility .

  • Proteolytic processing: PAK1 may undergo partial degradation during sample preparation.

  • Cross-reactivity: Some antibodies may detect related PAK family members (PAK2, PAK3) .

Research has identified at least three distinct bands attributable to PAK1 on large gels, with bands sometimes designated as PAK1-0, PAK1-1, and PAK1-2 . Interestingly, alkaline phosphatase treatment, while reducing phospho-specific signals, does not substantially alter the multiple band pattern, suggesting that factors beyond phosphorylation contribute to this phenomenon . This indicates that the complex band pattern may reflect structural variations rather than simply different phosphorylation states.

How do I reconcile contradictory results between different phospho-PAK1 antibodies?

Reconciling contradictory results between different phospho-PAK1 antibodies requires systematic analysis:

  • Epitope comparison: Different antibodies may recognize distinct epitopes surrounding the phosphorylation site, leading to varied sensitivity to neighboring modifications.

  • Validation techniques: Apply multiple validation approaches for each antibody, including phosphatase treatment, siRNA knockdown, and mutant analysis .

  • Antibody affinity considerations: Some antibodies show preferential binding to certain forms of PAK1; for example, ab131522 detects exogenous but not endogenous PAK1 in certain contexts .

  • Technical replication: Repeat experiments using standardized conditions to confirm reproducibility.

  • Complementary approaches: Use mass spectrometry or other non-antibody-based methods to verify phosphorylation status.

Research has demonstrated that the affinity of some PAK1 antibodies is affected by phosphorylation states . When contradictory results arise, consider that different antibodies may be detecting distinct subpopulations of PAK1 or may be differentially sensitive to conformational changes induced by multiple phosphorylation events.

How can I assess the functional significance of PAK1 Ser199 phosphorylation?

Assessing the functional significance of PAK1 Ser199 phosphorylation requires a multi-faceted approach:

  • Kinase activity assays: Measure PAK1 kinase activity using substrates like VASP-(158-277), comparing wild-type PAK1 with S199A (phospho-null) and S199E (phosphomimetic) mutants .

  • Cell migration assays: Since PAK1 regulates cell migration, compare migration rates in cells expressing wild-type versus mutant PAK1 .

  • Interaction studies: Determine if Ser199 phosphorylation affects PAK1 interactions with binding partners using co-immunoprecipitation or proximity ligation assays.

  • Temporal analysis: Investigate the timing of Ser199 phosphorylation relative to other phosphorylation events and cellular processes.

  • Pathway analysis: Examine downstream signaling events affected by Ser199 phosphorylation status.

Research has shown that phosphorylation of PAK1 at different sites can have distinct functional consequences. For example, Thr109 phosphorylation by LKB1 suppresses PAK1 activity and cell migration . Similar methodologies can be applied to understand the specific role of Ser199 phosphorylation in regulating PAK1 function.

What is the relationship between PAK1 Ser199 phosphorylation and Ser144 autophosphorylation?

The relationship between PAK1 Ser199 phosphorylation and Ser144 autophosphorylation represents a complex regulatory network:

  • Sequential phosphorylation: Research suggests a potential sequential relationship, where phosphorylation at one site may precede or facilitate modification at the other site.

  • Functional implications: While Ser144 phosphorylation is associated with PAK1 activation , the functional significance of Ser199 phosphorylation may differ depending on cellular context.

  • Regulatory mechanisms: Different upstream kinases may target these sites independently; Ser144 is an autophosphorylation site, while other kinases may target Ser199.

  • Conformational effects: Phosphorylation at either site may induce conformational changes affecting accessibility of the other site.

Interestingly, research has shown that exogenous expression of PAK1 variants results in proteins that appear minimally phosphorylated at Ser144, with phosphorylation levels reduced to approximately 60-70% compared to endogenous PAK1 . This suggests complex regulatory mechanisms governing the phosphorylation status of different PAK1 sites that may be disrupted when the protein is overexpressed.

How do I address inconsistent phospho-PAK1 (Ser199) signal in my experiments?

Addressing inconsistent phospho-PAK1 (Ser199) signals requires systematic troubleshooting:

Problem SourcePotential Solutions
Sample Preparation- Use fresh samples with phosphatase inhibitors
- Standardize protein extraction protocols
- Avoid freeze-thaw cycles
Antibody Quality- Validate antibody specificity with controls
- Test multiple antibody lots
- Optimize antibody concentration
Detection System- Ensure ECL reagents are fresh
- Optimize exposure time
- Consider fluorescent-based detection for quantitation
Biological Variability- Standardize cell culture conditions
- Control for cell density and passage number
- Synchronize cells if appropriate
Technical Variation- Standardize gel running conditions
- Ensure complete transfer to membrane
- Use loading controls for normalization

Research demonstrates that PAK1 phosphorylation can be dynamic and influenced by multiple factors . Additionally, the relative intensity of different PAK1 bands can vary depending on the antibody used , so consistent use of the same antibody and standardized experimental conditions is crucial for obtaining reproducible results.

What strategies can I use to distinguish between phospho-PAK1 and phospho-PAK2 in complex samples?

Distinguishing between phospho-PAK1 and phospho-PAK2 in complex samples requires specialized approaches:

  • Molecular weight discrimination: PAK1 (68-74 kDa) and PAK2 (61-67 kDa) can be partially resolved on gradient gels with extended separation times .

  • Isoform-specific immunodepletion: Deplete samples of one isoform using specific antibodies before analyzing for the other.

  • Genetic approaches: Use cell lines with CRISPR/Cas9-mediated knockout of either PAK1 or PAK2 as controls.

  • Recombinant protein standards: Run purified phosphorylated PAK1 and PAK2 as reference standards.

  • Mass spectrometry: Employ phospho-peptide mapping to definitively identify isoform-specific phosphorylation events.

Research has shown that while PAK2 typically appears as a single dominant band, PAK1 manifests as multiple bands between 60-70 kDa . This characteristic pattern can aid in distinguishing between these related proteins. Additionally, combining antibodies that recognize different epitopes on these proteins can provide complementary information to improve discrimination.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.